ArticleWorld journal of gastroenterology2025
Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association of triglyceride-glucose index with cancer incidence and mortality: a systematic review and meta-analysis of cohort studies.Frontiers in endocrinology · 2025Pooled it
- The oncogenic role, regulatory mechanism, and clinical significance of lncRNA HIF1A-AS2 in multiple human cancers.Clinical and experimental medicine · 2026Review
- Development and validation of a preoperative glycolipid metabolism-based nomogram for predicting postoperative recurrence in primary glioma: a retrospective cohort study.Lipids in health and disease · 2026Article
- Triglyceride-to-glucose index and lymphocyte-to-monocyte ratio enhance prognostic accuracy for colorectal cancer patients: a multicenter machine learning cohort study.Translational cancer research · 2026Article
- The correlation between the triglyceride-glucose index and the odds of cervical cancer.Frontiers in oncology · 2026Article
- Prognostic significance of preoperative C-reactive protein-triglyceride-glucose index in long-term outcomes after radical gastrectomy for gastric cancer.World journal of gastrointestinal oncology · 2025Article
- Triglyceride-glucose index in predicting gastric cancer prognosis: A need for caution.World journal of gastroenterology · 2025Article
- Triglyceride-glucose index as a prognostic indicator in advanced gastric cancer: Insights and future research.World journal of gastroenterology · 2025Article
- Prognostic value of the triglyceride-glucose index in gastric cancer.World journal of gastroenterology · 2025Article
- Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration.World journal of gastroenterology · 2025Article
- Prognostic significance of the lymphocyte-to-high-density lipoprotein ratio in long-term efficacy of combined immunotherapy for advanced non-small cell lung cancer.Frontiers in oncology · 2025Article
- Association of the triglyceride-glucose index with immunotherapy efficacy and long-term prognosis in advanced Non-small cell lung cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the fifth most common malignancy and the third leading cause of death worldwide. Despite advancements in immunotherapies, patient prognosis remains poor, necessitating the identification of key prognostic factors to optimize the treatment approaches. Insulin resistance, as indicated by the triglyceride glucose (TyG) index, is increasingly recognized for its impact on cancer progression and immune modulation, and its potential role in GC prognosis is of particular interest.
aimTo investigate whether the TyG index, a surrogate marker of insulin resistance, can predict the prognosis of patients with advanced GC receiving immunotherapy combined with chemotherapy.
methodsThis retrospective study included 300 patients with advanced GC who received sintilimab combined with chemotherapy. The patients were categorized into two groups according to high or low TyG index, and independent prognostic factors for overall survival (OS) were determined using Cox proportional hazards regression analysis, which led to the development of a nomogram model.
resultsOf the included patients, 136 had a high TyG index and 164 had a low TyG index. The median progression-free survival of the high TyG index group was significantly longer than that of the low TyG index group. Similarly, the median OS of the high TyG index group was significantly longer than that of the low TyG index group. The objective response and disease control rates in the two groups were 18.38%
conclusionThe TyG index is a long-term predictor of the efficacy of immunotherapy combined with chemotherapy, and patients with a high index have a better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.